Background: Pharmacological activation of cannabinoid receptors elicits antitumoral responses in different cancer models. However, the biological role of these receptors in tumor physio-pathology is still unknown.
The classical and the most recent molecular classification of breast cancer recognizes a specific entity characterized by the overexpression of the tyrosine kinase receptor (TKR) human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2) (1) (2) (3) (4) . Activation of TKRs turns on key signaling pathways involved in cell proliferation, development, differentiation, and angiogenesis, among other processes (5) . HER2 gene amplification/protein overexpression is detected in 20% to 30% of primary breast cancers and is a predictor of poor prognosis and deficient response to chemotherapy (6) .
The endocannabinoid system (ECS) is a cell communication system that participates in the control of different physiological functions such as pain perception, motor behavior, and food intake, just to mention a few (7, 8) . It consists of two cannabinoidspecific G protein-coupled receptors (GPCRs), CB 1 and CB 2 , their endogenous ligands, and the enzymes that produce and metabolize these ligands (7, 8) . A large number of studies demonstrate that the pharmacological activation of the ECS by different strategies (eg, activation of cannabinoid receptors, inhibition of endocannabinoid degradation) leads to antitumoral responses (7) (8) (9) (10) (11) . Additionally, it has been shown that the ECS is deregulated in a variety of cancers (7, (12) (13) (14) . Although strong evidence points to the cannabinoid receptor CB 2 as a drug target for antitumoral therapy in several types of cancer (11, 14, 15) , there is no information on its role in tumor generation and progression. Here we show an unprecedented pro-oncogenic role of the cannabinoid receptor CB 2 in HER2+ breast cancer and unveil that this GPCR is a pivotal regulator of HER2 signaling.
Methods

Tissue Microarrays
PFA-fixed and paraffin-embedded blocks of tumor tissue from cases operated in the University Hospitals of Kiel, Tübingen, or Freiburg between 1997 and 2010 were used for tissue microarray (TMA) construction. All patients gave informed consent, and the study was authorized by the respective Hospital Ethics Committees. TMAs were generated by punching two 1 mm spots of each patient's sample. This resulted in two series of 166 and 483 tumor samples. Complete histopathological information was available for all the patients. Additionally, for the 483-sample series (TMA #2), date and cause of death as well as date of local and/or distant relapse were also available.
Immunohistochemical Analysis
Tissue sections were subjected to a heat-induced antigen retrieval step prior to exposure to an anti-CB 2 receptor or an anti-ERBB2 primary antibody (Supplementary Table 1 , available online). Immunodetection was performed using the Envision method with DAB as the chromogen. For CB 2 expression, cases were scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (high staining). ERBB2 staining was scored by one independent pathologist in each institution (University Hospitals of Kiel, Tübingen, or Freiburg) in accordance with HercepTest manufacturer's guidelines.
Generation of MMTV-neu:CB 2 -/-Mice and Sample Collection
All procedures involving animals were performed with the approval of the Complutense University Animal Experimentation Committee according to the EU official regulations. Generation of the congenic strain MMTV-neu:CB 2 -/-was accomplished by mating MMTV-neu mice with CB 2 -/-mice (see the Supplementary Methods, available online). Females were palpated twice weekly for mammary gland nodules. As soon as tumors appeared, they were routinely measured with external caliper, and volume was calculated as (4π/3) x (width/2) 2 x (length/2). Animals were sacrificed and mammary glands, breast tumors, and lungs were collected (see the Supplementary Methods, available online) at the following time points: 1) when the first tumor in each animal appeared, 2) 40 days after the appearance of the first tumor, and 3) 90 days after the appearance of the first tumor.
Statistical Analysis
The Pearson's chi-squared test was used for statistical analysis of the human samples included in the TMAs. Kaplan-Meier survival curves were statistically compared by the log-rank test. Analysis of variance (ANOVA) with a post hoc analysis by the StudentNewman-Keuls' test was routinely used for the rest of the analyses. Unless otherwise stated, data are expressed as mean ± SD. All statistical tests were two-sided, unless otherwise specified. A P value of less than .05 was considered statistically significant.
Additional methods are available in the Supplementary Methods (available online).
Results
Prognostic Relevance of Tumor CB 2 Expression
In two small cohorts of human samples, we previously reported that CB 2 mRNA expression is associated with higher histological grades and increased HER2 expression (16) and that the CB 2 protein was present in the vast majority of HER2+ tumors (17) . Here, we analyzed CB 2 expression in a much larger series of tissue sections (649 breast human samples included in different tissue microarrays [TMAs]). CB 2 expression was scored as 0 (no staining), 1 (weak staining), 2 (moderate staining), or 3 (high staining) ( Figure 1A ). We observed that nontumor article breast tissue expressed undetectable levels of CB 2 ( Figure 1B) . Conversely, CB 2 was expressed by a very large fraction of human breast adenocarcinomas (476 out of 629, ie, 75.6%). CB 2 expression was highly associated to HER2+ tumors (P < .001) ( Figure 1C ), while no association between CB 2 expression and hormone-sensitive (P = .66) or triple-negative tumors (P = .14) was detected ( Figure 1C) . Thus, 96.7% of the HER2+ samples scored positive for CB 2 expression ( Figure 1C) . Moreover, 65.2% of them expressed elevated levels of CB 2 (scores 2 and 3) ( Figure 1C ). Importantly, these HER2+/high CB 2 patients had decreased overall survival (hazard ratio [HR] = 0.29, 95% confidence interval [CI] = 0.09 to 0.71, P = .009]) ( Figure 2A ) and higher probability for suffering local recurrence (HR = 0.09, 95% CI = 0.049 to 0.54, P = .003) ( Figure 2B ) and for developing distant metastases (HR = 0.33, 95% CI = 0.13 to 0.75, P = .009) ( Figure 2C ) than HER2+/low CB 2 (scores 0 and 1) patients. Similar observations were made when CB 2 mRNA levels were analyzed in public DNA microarray datasets (HR = 0.25, 95% CI = 0.07 to 1.05, P = .06 in Figure 2D ; HR = 0.43, 95% CI = 0.18 to 0.94, P = .04 in Figure 2E ; and HR = 0.52, 95% CI = 0.33 to 0.83, P = .007 in Figure 2F ) (18) (19) (20) . Of interest, this association was not observed in HER2-patients (Figures 2G-I ; HR = 0.71, 95% CI = 0.30 to 1.56, P = .36 in G; HR = 0.83, 95% CI = 0.36 to 1.86, P = .64 in H; and HR = 0.48, 95% CI = 0.14 to 1.30, P = .14 in I). Together, these results show a strong association between CB 2 expression and tumor aggressiveness in HER2+ breast cancer.
Impact of CB 2 Knock-out on Breast Tumor Generation and Progression
We next analyzed whether there was a cause and effect link between elevated CB 2 expression and increased aggressiveness in HER2+ tumors. First, we observed that CB 2 expression in the noncancerous mammary glands of adult wild-type (WT) female mice was virtually undetectable (Supplementary Figure 1, A and B , available online). Moreover, it remained very low and unchanged during adult mammary gland development (Supplementary Figure 1 , A and B, available online). These results suggest that CB 2 may not play a major role in the physiology of the healthy adult mammary gland. Next, we analyzed breast tumor generation and progression in an animal model of HER2-driven breast cancer (the MMTV-neu mouse) in which CB 2 expression was knocked out (Supplementary Figure 2 , A and B, available online). MMTV-neu:CB 2 -/-mice (n = 42) showed a striking delay in tumor onset as compared with their WT littermates (n = 67) (P = .03) ( Figure 3A) . Upon early detection, tumor histological features were very similar in both groups (low-grade adenocarcinomas with no lymphatic invasion) (Supplementary Figure 2C , available online), the only apparent difference between them being their mitotic index (medium in WT animals and low in the CB 2 -/-population) (Supplementary Figure 2C, The lack of CB 2 receptors also reduced the number of tumors generated per animal (P = .03) ( Figure 3B ) and slowed down tumor growth (P = .003) ( Figure 3C ). The delayed tumor onset and the decreased tumor multiplicity and growth associated with the lack of CB 2 receptors were accompanied by reduced levels of cyclin D1 and increased levels of the CDK inhibitor p21 in the tumors (Figure 3 , D and E), both of which are hallmarks of HER2-induced malignant transformation and progression (21) (22) (23) . Additionally, the levels of the endocannabinoid anandamide were higher in CB 2 -/--derived tumors than in CB 2 +/+ tumors (Supplementary Figure 2D, In (D-E), samples were ranked by CB 2 mRNA expression, and the best cutoff was manually selected.
In (F), the best cutoff was automatically selected by the software. Survival curves were statistically compared by the log-rank test. All statistical tests were two-sided. Newman-Keuls' test. * P < .05; ** P < .01 vs MMTV-neu:CB 2 WT mice. All statistical tests were two-sided.
article
WT lesions (Supplementary Figure 2E , available online). Finally, CB 2 deficiency produced a remarkable reduction in the percentage of animals with lung metastases ( Figure 3F ). This phenotype associated with decreased tumor levels of tenascin-C, SPARC, and COX2 ( Figure 3G ), which have been proposed to mediate metastasis specifically directed to the lungs (24) . Together, these results indicate that CB 2 plays an important role in promoting HER2+ breast tumor generation and progression.
Mechanistic Insight into the Association Between CB 2 and HER2 Expression
Because we observed that virtually all HER2+ human tumors express CB 2 (Figure 1 ), we analyzed whether HER2 controls the expression of the cannabinoid receptor. Ectopic overexpression of HER2 in triple-negative (no estrogen receptor, progesterone receptor, and HER2 expression) MDA-MB-231 cells resulted in an increased transcription of CB 2 ( Figure 4A ). The in silico analysis of the CB 2 promoter sequence revealed the existence of, among others, several ELK1-binding sites (25) (Supplementary Figure 3A , available online). ELK1 belongs to the ETS transcription factor family, which has been related to cancer (26) and is a well-established target of the ERK cascade (27) . We observed that HER2 overexpression activated ELK1, an effect that was accompanied by the activation of ERK ( Figure 4B ). Of interest, incubation with the MEK inhibitor U0126 prevented the enhancement of p-ELK1 levels ( Figure 4B ). Moreover, pharmacological inhibition of MEK ( Figure 4C ) and genetic knock-down of ELK1 ( Figure 4D ; Supplementary Figure 3B , available online) blocked the increase in CB 2 mRNA levels elicited by HER2 overexpression. Likewise, ELK1 knock-down (Supplementary Figure 3C , available online) decreased CB 2 mRNA levels in breast cancer cells that endogenously overexpress HER2, an effect that was not observed in HER2-negative cells ( Figure 4E ). By chromatin immunoprecitation assays, we confirmed that ELK1 physically interacts with the CB 2 promoter and that this interaction is enhanced upon HER2 overexpression and is prevented by inhibition of the ERK cascade ( Figure 4F ). Moreover, ELK1 was able to activate the CB 2 promoter. Thus, transfection of HEK293T cells with a luciferase reporter encoding the CB 2 gene promoter (pGL3-CB 2 ) together with a constitutively active ELK1-expressing plasmid resulted in an increased luciferase activity when compared with cells transfected with pGL3-CB 2 only ( Figure 4G ). Point mutations in the CB 2 promoter revealed that the putative ELK1-binding sites located at positions -71 and -89 are the ones responsible for ELK1-induced activation of CB 2 expression ( Figure 4G ).
Together, these observations demonstrate that HER2 promotes CB 2 upregulation by activating the transcription factor ELK1 via ERK activation. Supporting the relevance of this observation, the analysis of 1453 human breast cancer samples from seven different public DNA microarrays (19, (28) (29) (30) (31) (32) (33) showed a strong association (P < .001) between ELK1 and CB 2 mRNA expression ( Figure 4 , H and I), and the immunofluorescence analysis of HER2+ breast cancer biopsies revealed that CB 2 -positive cancer cells presented nuclear ELK1 immunoreactivity ( Figure 4J ).
Analysis of the Potential Molecular Interaction
Between HER2 and CB 2 We wanted to determine whether the HER2-CB 2 functional crosstalk was the result of a molecular interaction between the receptors. Immunofluorescence analysis of human HER2+ breast cancer cells revealed that the two receptors colocalize ( Figure 5A ). Moreover, immunoprecipitation of HER2 in HEK cells produced the coprecipitation of CB 2 , and vice versa ( Figure 5B ). The HER2-CB 2 molecular association in cancer cells was confirmed using the proximity ligation assay. Thus, ectopic overexpression of HER2 in MDA-MB-231 cells enhanced the levels of CB 2 ( Figure 5C ), and this effect was accompanied by the appearance of fluorescent dots, ie, HER2-CB 2 heteromers ( Figure 5D ). This fluorescent signal was not evident either in cells that do not express HER2 (with very low levels of CB 2 ) or in cells in which CB 2 expression was knocked down by means of selective shRNA ( Figure 5D ). Importantly, the presence of HER2/CB 2 heterodimers was detected in human breast cancer cells that endogenously overexpress HER2 ( Figure 5E ) and in HER2-positive human breast cancer tissue ( Figure 5F ). Again, the heteromer fluorescent signal was not evident either when CB 2 was stably silenced in cells ( Figure 5E ) or in tumors that do not overexpress HER2 ( Figure 5F ). These results confirm that CB 2 is upregulated by HER2 and support that HER2 and CB 2 form heteromers in cancer cells.
Role of CB 2 in the Control of the Pro-oncogenic Features of HER2+ Breast Cancer Cells
We next analyzed the biological consequences of the HER2-induced CB 2 upregulation. HER2 overexpression in MDA-MB-231 cells (which effectively enhanced CB 2 levels) ( Figure 5C ) increased cancer cell viability ( Figure 6A ) and stimulated properties of cancer cells intimately related to tumor progression, ie, invasion ( Figure 6B ) and anchorage-independent growth ( Figure 6C ). These effects were prevented by CB 2 knock-down ( Figure 6 , A-C). Likewise, genetic silencing of CB 2 (Supplementary Figure 3D , available online) reduced cell viability ( Figure 6D ), cell invasion ( Figure 6E ), colony formation in soft agar ( Figure 6F ), and the expression of metastasis markers (Supplementary Figure 3E , available online) in cells endogenously overexpressing HER2, an effect that was not observed in HER2-negative cells. Moreover, the growth of MDA-MB-231 HER2-overexpressing orthotopic xenografts ( Figure 6G ) and the generation of lung metastases (Figures 6, H and I; Supplementary Figure 3F , available online) were statistically significantly impaired upon stable CB 2 knockdown (Supplementary Figure 3G , available online). Similarly, tumors generated from HER2-amplified cells statistically significantly reduced their growth when CB 2 was silenced ( Figure 6J ). Collectively, these data show that CB 2 promotes pro-oncogenic responses in a HER2+ context.
Potential Targets of CB 2 -HER2 Pro-oncogenic Signaling
Next, we wanted to identify CB 2 targets responsible for its protumoral activity. Upon modulation of CB 2 and HER2 expression and by means of a phospho-kinase array, we detected substantial alterations in some members of the SRC family of nonreceptor tyrosine kinases, which has been extensively related to cancer (34) (35) (36) . Specifically, we found that the expression of phosphorylated LYN, LCK, YES, FGR, HCK, and FYN decreased upon CB 2 knock-down (Supplementary Figure 4 , A and B, available online). However, this effect was observed both in HER2+ and HER2-cells (Supplementary Figure 4 , A and B, available online), which suggests that, although these may be relevant CB 2 targets in breast cancer, they are not HER2+ context specific. Of interest, the phosphorylated form of another member of the SRC family (c-SRC), which has particular relevance in cancer development and progression (34), was specifically upregulated upon HER2 article * CB 2 mRNA expression (a.u.) Figure 7B ). Likewise, a decrease in p-c-SRC upon CB 2 silencing was observed in a panel of five breast cancer cell lines that endogenously overexpress HER2 ( Figure 7C ). Next, we tested whether c-SRC was responsible for CB 2 -driven oncogenesis. First, we observed that mouse NIH/3T3 embryonic Data were analyzed by analysis of variance with a post hoc analysis by the Student-Newman-Keuls' test (n ≥ 3 independent experiments, except in [G-J]). * P < .05 and ** P < .01 vs the corresponding shC cell line; † P < .01 vs shC-231-HER2 cells. All statistical tests were two-sided. article fibroblasts acquire clonogenic properties upon overexpression of either CB 2 or HER2 (Figure 8, A and B) . Moreover, the ability of these cells to form colonies in soft agar statistically significantly increased when the two receptors were simultaneously overexpressed ( Figure 8, A and B) . Disruption of c-SRC signaling by using a c-SRC-dominant negative construct prevented the oncogenic phenotype induced by CB 2 plus HER2 ( Figure 8, A and  B) . Of interest, while the HER2-mediated increased clonogenicity was prevented by blocking c-SRC signaling, the CB 2 -induced clonogenic response was not (Figure 8, A and B) , which indicates that CB 2 promotes c-SRC activation (and the subsequent clonogenic response) via HER2. We then performed colony formation experiments with human HER2-amplified breast cancer cells. Specifically, we overexpressed CB 2 in five HER2+ cell lines and observed an increase in the levels of p-c-SRC ( Figure 8C ). As expected, this increase in activated c-SRC was accompanied by an enhanced clonogenicity ( Figure 8D ). Importantly, pharmacological inhibition of c-SRC with Saracatinib (a SRC family/ Abl dual-kinase inhibitor) in CB2-overexpressing cells kept both clonogenicity ( Figure 8D ) and p-c-SRC expression ( Figure 8C ) at the same level as in pcDNA3-transfected cells treated with the inhibitor, which further suggests that CB 2 -driven oncogenesis is mediated by c-SRC activation. Finally, and in further support of a causal link between the CB 2 /HER2/c-SRC axis and pro-oncogenic events, we found a decreased c-SRC and AKT activation in tumors generated by CB 2 -deficient animals (which present a less aggressive phenotype [ Figure 3] ) with respect to their WT littermates ( Figure 8, E and F) , and the analysis of human tumor biopsies revealed that HER2+ breast cancer cells expressing activated c-SRC also expressed CB 2 ( Figure 8G) .
Discussion
Here we demonstrate not only that the cannabinoid receptor CB 2 exerts a remarkable pro-oncogenic function in HER2+ breast cancer but also that CB 2 plays a pivotal role in HER2-mediated pro-oncogenic signaling ( Figure 8H ). It is widely accepted that GPCRs and TKRs control critical biological processes intimately related to oncogenesis and that the functional cross-talk between members of these two receptor superfamilies (eg, transactivation of TKRs by GPCR-mediated signaling) may have important consequences in the progression and resistance to TKR-targeted therapies of some types of cancer (37, 38) , including HER2+ breast cancer (39) . In some cases, the functional cross-talk between GPCRs and TKRs might rely on a physical interaction between receptors. Regarding HER2 specifically, it has been reported that this receptor can form a complex with the β2-adrenergic receptor in the heart and brain, which is required for mitogen-activated protein kinase activation induced by multiple GPCR agonists in cardiac myocytes (40) . Here we show for the first time that a TKR (HER2) forms heteromers with a GPCR (CB 2 ) in cancer cells. These findings reveal an unprecedented mechanism of control of HER2 activity that involves cannabinoid receptor CB 2 , and they suggest that the simultaneous targeting of the two receptors (or common downstream effectors) may be a reasonable therapeutic strategy. Because dual-targeting approaches are showing positive results in preclinical and clinical contexts when the targets are different members of the ERBB family (mainly ERBB1 and ERBB2) or even different domains of the same receptor (neutralizing antibodies + tyrosine kinase inhibitors, for example) (41), it is tempting to speculate that the combination of anti-HER2 compounds with cannabinoids targeting CB 2 may have synergistic antitumoral effects. Interestingly, there is evidence showing that, at least at the preclinical level, the combination of cannabinoids with other anticancer therapies results in improved responses when compared with the corresponding individual treatments (11, (42) (43) (44) (45) . It would therefore be desirable that future clinical trials determine whether these preclinical findings can be extrapolated to the cancer patient.
Our findings also show that the nonreceptor tyrosine kinase c-SRC plays a pivotal role in CB 2 -induced HER2 pro-oncogenic signaling (Figure 7 ). c-SRC promotes cell proliferation, survival, migration, and angiogenesis (34) , and its deregulation is associated with oncogenesis (35, 36) and poor patient prognosis (46) . Together, these features made c-SRC an excellent target for the clinical development of specific inhibitors (35, 36, 46, 47) . In HER2+ breast cancer in particular, c-SRC activation has been implicated in the generation of brain metastases (48), a condition that has no curative treatment, and in the development of trastuzumab resistance (49) . Interestingly, treatment of brain metastasis-bearing mice with a combination of Lapatinib (which targets ERBB1 and ERBB2) and a c-SRC inhibitor slowed down the growth of the metastases (48) , and treatment of trastuzumab-resistant cells/tumors with a c-SRC inhibitor restored trastuzumab response (49) . These data suggest that blocking c-SRC may be an effective manner to treat two important remaining clinical challenges in HER2+ breast cancer: the management of highly metastatic tumors (especially those colonizing the central nervous system) and trastuzumab resistance (both innate and acquired). Nonetheless, additional experiments should be performed to analyze the involvement of CB 2 in c-SRC-mediated trastuzumab resistance and generation of brain metastases. and densitometric analysis (right panels) of phospho-c-SRC (E) and phosphor-AKT (F) in breast tumors generated by MMTV-neu:CB 2 WT and MMTV-neu:CB 2 KO mice.
G)
Immunofluorescence analysis of CB 2 (green) and phospho-c-SRC (red) in a human HER2+ breast tumor sample. Cell nuclei are stained in blue. Scale bar = 100 µm.
H) Proposed role of CB 2 in HER2-driven pro-oncogenic signaling: HER2 enhances CB 2 expression by activating the transcription factor ELK1 via ERK. Increased CB 2 expression promotes HER2 pro-oncogenic signaling by activating the tyrosine kinase c-SRC. Data were analyzed by analysis of variance with a post hoc analysis by the Student-Newman-Keuls' test. * P < .05 and ** P < .01 vs pcDNA3; † P < .05 vs CB 2 or HER2; ‡ P < .01 vs HER2; § P < .05 vs HER2-CB 2 (A and D). * P < .05 vs MMTV-neu:CB 2 WT mice (E and F). All statistical tests were two-sided.
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Our results clearly reveal a pro-oncogenic role of CB 2 in HER2+ breast cancer. However, it has been widely described that pharmacological activation of this particular receptor exerts antitumoral effects in different models of breast (14, 16, 17, 50, 51) and many other types of cancer (11) . Further experiments should be performed to get a deeper insight into the molecular details of this bimodal effect of CB 2 receptor functionality. For example, it would be interesting to know whether different cannabinoid stimuli (ie, an endogenous tone vs an exogenous pharmacological activation) produce a different activation of CB 2 /HER2-mediated signaling in terms of intensity and/or specific pathways.
Finally, we have observed a strong association between higher CB 2 protein expression in HER2+ breast tumors and lower patient overall relapse-free and metastasis-free survival. It has been previously shown that the levels of CB 2 are elevated in breast (16, 17, 51) and many other types of cancer compared with healthy matching tissue (11) and in the more aggressive (highgrade) breast (16, 17 ) and brain (52) (53) (54) tumors compared with the respective less aggressive (low grade) tumors. Recently, an association between CB 2 expression and overall and disease-free survival of patients with squamous cell carcinoma of the head and neck has also been reported (55) . All these observations may serve to exploit CB 2 as a new prognostic marker in oncology (at least in certain types of tumors).
In conclusion, here we present solid insight into an unprecedented pro-oncogenic effect of the CB 2 -HER2 signaling axis. However, we acknowledge some limitations in our study. First, the cell and animal models used in this study are well validated on translational grounds, but they do not fully recapitulate the pathology found in the actual HER2+ breast cancer patient. In this respect, although we have been able to unravel a strong association between CB 2 expression in human HER2+ tumor specimens and the prognosis of the donor patients, it would be desirable that this association be established in larger patient populations to further support the potential impact of our observations on therapeutic decision-making. This should be ideally accompanied by clinical studies aimed at evaluating the safety and efficacy of strategies targeting, for example, CB 2 and SRC, in combination with widely accepted anti-HER2+ breast cancer chemotherapies and immunotherapies. Additionally, although our findings support the existence of HER2-CB 2 heteromers, further studies should be performed to unveil the functional relevance of these complexes in human breast cancer and whether-and, if so, how-they actually drive CB 2 /HER2-evoked signaling at different stages of tumor malignancy. Notwithstanding such limitations, our study provides the first proof of concept on the action of CB 2 as a new key player in HER2+ breast cancer biology. 
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